SCHEMBL2172090

SCHEMBL2172090

Cc1ccc(S(=O)(=O)Nc2ccc(C)c(NC3CCN(C)CC3)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
ALDH1A1 P00352 4/20 0.49
LMNA P02545 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
THRB P10828 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP3A4 P08684 1/20 0.47
BRD4 O60885 4/20 0.47
HSD17B10 Q99714 1/20 0.46
KCNA1 Q09470 1/20 0.46
KCNAB1 Q14722 1/20 0.46
MAPT P10636 4/20 0.46
TP53 P04637 2/20 0.45
ATM Q13315 1/20 0.45
RECQL P46063 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6117477 0.91 TP53 (0.47) POLBALDH1A1LMNASMN1; SMN2CYP3A4
SCHEMBL2170725 0.91 CYP3A4 (0.50) POLBALDH1A1LMNASMN1; SMN2CYP3A4
SCHEMBL2169909 0.90 CYP3A4 (0.54) POLBALDH1A1LMNASMN1; SMN2THRB
SCHEMBL2169531 0.89 HTR6 (0.49) POLBALDH1A1LMNASMN1; SMN2CYP3A4
SCHEMBL2183002 0.89 CYP3A4 (0.49) POLBALDH1A1LMNASMN1; SMN2THRB
Hydrochloric Acid SCHEMBL2183767 0.88 HTR6 (0.48) POLBSMN1; SMN2CYP3A4MAPTMEN1
SCHEMBL2172325 0.87 CYP3A4 (0.60) ALDH1A1LMNASMN1; SMN2THRBL3MBTL1
SCHEMBL2184543 0.83 FFAR1 (0.50) POLBALDH1A1LMNASMN1; SMN2THRB
SCHEMBL2170217 0.81 SMN1; SMN2 (0.49) POLBALDH1A1LMNASMN1; SMN2CYP3A4
SCHEMBL2169541 0.80 CYP3A4 (0.52) POLBLMNACYP3A4BRD4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346847-B1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2013-05-15 EP claimed
US-8404720-B2 Aryl sulfonamide amine compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2013-03-26 US claimed
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2012-05-24 US claimed
EP-2346847-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2011-07-27 EP claimed
WO-2010032258-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO claimed
EP-2346847-B1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2013-05-15 EP disclosed
US-8404720-B2 Aryl sulfonamide amine compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2013-03-26 US disclosed
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2012-05-24 US disclosed
EP-2346847-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2011-07-27 EP disclosed
WO-2010032258-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR1A, HTR5A POLB 4201/4885ALDH1A1 937/4885LMNA 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.